Effects of Elobixibat in Patients with Diabetes and Concomitant Chronic Constipation: an 8-week, Prospective, Single-center, Single-arm Study.

ABSTRACT:

Aims

To evaluate the efficacy and safety of elobixibat in patients with diabetes and concomitant chronic constipation.

Methods

This was a single-center, single-arm study. Thirty-three patients with diabetes and chronic constipation, as defined by the Rome IV criteria, were treated with elobixibat (10 mg/day) for 8 weeks. Patients recorded stool properties, including spontaneous bowel movements (SBMs) and stool consistency, according to the Bristol Stool Form Scale (BSFS). Quality of life for constipation was evaluated with the Japanese version of the Patient Assessment of Constipation Quality of Life (JPAC-QOL).

Results

Of the 33 eligible patients, 30 completed the study. Elobixibat significantly increased the median (interquartile range) frequency of SBMs per week, f

SUBMITTER: Hishida Y 

PROVIDER: S-EPMC9402500 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature